2-氯甲基-1,4-苯并二噁烷 | 2164-33-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 中文名称: 2-氯甲基-1,4-苯并二噁烷
• 中文别名: 2-氯甲基-1,4-苯并二恶烷；2-氯甲基-1,4-苯并二恶烷
• 英文名称: 2-chloromethyl-1,4-benzodioxane
• 英文别名: 2-chloromethyl-2,3-dihydro-1,4-benzodioxin；2-(chloromethyl)-2,3-dihydro-1,4-benzodioxin；2-chloromethyl-2,3-dihydro-benzo[1,4]dioxine；2-Chlormethyl-2,3-dihydro-benzo[1,4]dioxin；2-chloromethyl-1,4-benzodioxan；2-chloromethyl 2,3-dihydro [4H] 1,4-benzodioxin；2-(Chloromethyl)-2,3-dihydro-1,4-benzodioxine；3-(chloromethyl)-2,3-dihydro-1,4-benzodioxine
• CAS: 2164-33-2
• 化学式: C₉H₉ClO₂
• mdl: MFCD00014666
• 分子量: 184.622
• InChiKey: AYPKYQSHFKQVDL-UHFFFAOYSA-N

物化性质

• 沸点：
  96 °C
• 闪点：
  96°C/0.4mm

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  C
• 安全说明：
  S24/25
• 危险类别码：
  R34
• 海关编码：
  2932999099
• 储存条件：
  应贮存在阴凉、干燥的地方，并存放于密闭容器中，避免与不相容的物质接触。

SDS

Name:	2-(Chloromethyl)-2 3-dihydro-1 4-benzodioxine 97% Material Safety Data Sheet
Synonym:	2-Chloromethyl-1,4-benzodioxan
CAS:	2164-33-2

Section 1 - Chemical Product MSDS Name:2-(Chloromethyl)-2 3-dihydro-1 4-benzodioxine 97% Material Safety Data Sheet
Synonym:2-Chloromethyl-1,4-benzodioxan

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
2164-33-2	2-(Chloromethyl)-2,3-dihydro-1,4-benzo	97%	218-502-5

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 2164-33-2: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: colorless
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 96 deg C @0.4mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H9ClO2
Molecular Weight: 185

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, bases, amines.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 2164-33-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-(Chloromethyl)-2,3-dihydro-1,4-benzodioxine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE LIQUID, ACIDIC, ORGANIC, N.O.S.*
Hazard Class: 8
UN Number: 3265
Packing Group: III
IMO
Shipping Name: CORROSIVE LIQUID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3265
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE LIQUID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3265
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 2164-33-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 2164-33-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 2164-33-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氯甲基-1,4-苯并二噁烷 在 氢氧化钾 作用下， 以 甲醇 、 乙醇 为溶剂， 反应 9.0h， 生成 1-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)piperidine-4-carboxylic acid
  参考文献：
  名称：

  N-Substituted (2,3-Dihydro-1,4-benzodioxin-2-yl)methylamine Derivatives as D₂ Antagonists/5-HT_1A Partial Agonists with Potential as Atypical Antipsychotic Agents

  摘要：

  A series of N-substituted 1-(2,3-dihydro-1,4-benzodioxin-2-yl)methylamine derivatives with D-2 antagonist/5-HT1A partial agonist activity has been prepared as potential atypical antipsychotic agents. Optimization of in vitro receptor binding activity and in vivo activity in rodent models of psychosis has led to compound 24, which showed good affinities for human D-2, D-3, and 5-HT1A receptors but significantly less affinity for human alpha(1) adrenoceptors and rat H-1 and muscarinic receptors. In rodents, 24 showed functional D-2-like antagonism and 5-HT1A partial agonism. After oral dosing, 24 showed good activity in rodent antipsychotic tests and very little potential to cause extrapyramidal side effects (EPS), as measured by its ability to induce catalepsy in rats only at very high doses. In the light of this promising profile of activity, 24 has been selected for clinical investigation as a novel antipsychotic agent with a predicted low propensity to cause EPS.

  DOI：

  10.1021/jm9910122
• 作为产物：
  描述：

  邻苯二酚 在 氯化亚砜 、 potassium hydroxide 作用下， 以 氯仿 、 水 、 甲苯 为溶剂， 反应 6.0h， 生成 2-氯甲基-1,4-苯并二噁烷
  参考文献：
  名称：

  一种硫酸胍生合成方法

  摘要：

  本发明属于有机药物合成技术领域，具体涉及一种硫酸胍生合成方法，其包括如下步骤：1）将2‑羟甲基‑1,4‑苯并二恶烷与氯化亚砜在溶剂一存在条件下进行氯化反应，获得2‑氯甲基‑1,4‑苯并二恶烷；2）将2‑氯甲基‑1,4‑苯并二恶烷与胍在碱、溶剂二存在条件下进行缩合得到胍生，然后再与硫酸成盐得终产品硫酸胍生。该工艺合成步骤简单、路线短，原料毒性相对较小，而且所得产品的收率和纯度高。

  公开号：

  CN105061392B
• 作为试剂：
  描述：

  4-(苯甲酰基氨基)苯甲酸乙酯 在 2-氯甲基-1,4-苯并二噁烷 、 一水合肼 、 potassium hydroxide 作用下， 生成
  参考文献：
  名称：

  Synthesis of new biheterocycles containing a 1,4-benzodioxane fragment

  摘要：

  The reaction of 1,4-benzodioxane-2-carbonyl chloride with 5-(4-aminophenyl)-1,3,4-oxa- and -thiadiazole-2-thiols afforded new biheterocyclic compounds which were converted into the corresponding S-benzyl derivatives by treatment with benzyl chloride. 5-(4-Aroylaminophenyl)-1,3,4-oxa(thia)diazole-2-thiols reacted with 2-bromomethyl-1,4-benzodioxane to give compounds in which the 1,4-benzodioxane nucleus and fivemembered heterocycle are linked through a CH2S bridge.

  DOI：

  10.1134/s1070428014030233

文献信息

• Synthesis and Anti-Yeast Evaluation of Novel 2-Alkylthio-4-chloro-5-methyl-N-[imino-(1-oxo-(1H)-phthalazin-2-yl)methyl]benzenesulfonamide Derivatives
  作者：Jarosław Sławiński、Aneta Pogorzelska、Beata Żołnowska、Anna Kędzia、Marta Ziółkowska-Klinkosz、Ewa Kwapisz

  DOI：10.3390/molecules190913704

  日期：——

  are one of the main causes of hospital-related infections. Since conventional antifungals have become less effective because of the increasing fungal resistance to the standard drugs, the need for new agents is becoming urgent. Herein we report a synthesis of a series of novel N-[imino-(1-oxo-(1H)-phthalazin-2-yl)methyl]-benzenesulfonamide derivatives with in vitro activity against yeast-like fungi

  病原真菌是医院相关感染的主要原因之一。由于真菌对标准药物的耐药性不断增加，常规抗真菌药物的效果越来越差，因此迫切需要新的药物。在此，我们报道了一系列新型 N-[亚氨基-(1-氧代-(1H)-酞嗪-2-基)甲基]-苯磺酰胺衍生物的合成，这些衍生物具有体外抗酵母样真菌的活性，从口腔和念珠菌病患者的呼吸道。这些化合物是通过 1-(2-烷硫基苯磺酰基)-2-氨基胍与适当的邻羰基苯甲酸的一步或两步反应合成的。生物学研究表明，与参考药物氟康唑相比，新衍生物显示出显着的生长抑制活性，优于或相当。
• [EN] NOVEL PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISORDERS<br/>[FR] NOUVEAUX DERIVES DE PIPERAZINYL-PYRAZINONE POUR LE TRAITEMENT DES TROUBLES LIES AU RECEPTEUR 5-HT2A
  申请人：BIOVITRUM AB

  公开号：WO2004009586A1

  公开（公告）日：2004-01-29

  Compounds of the general formula (I): (I)wherein m, n, R1, R2, R3 and R4 are as described in the specification. Further included are pharmaceutical compositions comprising the compounds, processes for their preparation, as well as the use of the compounds for the preparation of a medicament for the treatment of 5-HT2A receptor-related disorders or medical conditions.

  通式（I）的化合物：（I）其中m、n、R1、R2、R3和R4如规范中所述。还包括包含这些化合物的药物组合物，它们的制备方法，以及利用这些化合物制备用于治疗5-HT2A受体相关疾病或医疗状况的药物的用途。
• Diphenylurea compounds
  申请人：——

  公开号：US20020025965A1

  公开（公告）日：2002-02-28

  1 wherein: R 1 , R 2 , R 3 and R 4 independently represent hydrogen, halogen, or alkyl, alkoxy, hydroxy, cyano, optionally substituted amino, nitro, carboxy, alkoxycarbonyl, optionally substituted aminocarbonyl or carbamoyl, L 1 and L 2 each represents hydrogen or together form —CH 2 —CH 2 —, X 1 , attached at the 2 or 3 position of the aromatic ring, represents a bond, and in that case X 2 represents hydrogen, halogen, or alkyl, alkoxy, hydroxy, nitro, cyano or optionally substituted amino, or X 1 and X 2 , together with two adjacent carbon to which they are bonded in the 2, 3 or 4 position of the aromatic ring, form a (C 4 -C 7 )cycloalkyl group, wherein one or two —CH 2 — of the cycloalkyl ring are optionally replaced by oxygen or NH, X 3 represents hydrogen, halogen, or alkyl, alkoxy, hydroxy, nitro, cyano or optionally substituted amino, G represents a group selected from: 2 wherein: the broken lines indicate the optional presence of a double bond, Alk represents linear or branched (C 1 -C 6 )alkylene, n is 0 or 1, T 3 represents alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or optionally substituted heteroarylalkyl, T 4 represents alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or optionally substituted heteroarylalkyl, and medicinal products containing the same are useful as dual &agr; 2 /5-HT 2c antagonist receptors.

  其中：R1、R2、R3 和 R4 分别代表氢、卤素或烷基、烷氧基、羟基、氰基、可选择地取代的氨基、硝基、羧基、烷氧羰基、可选择地取代的氨基羰基或氨基甲酰基，L1 和 L2 分别代表氢或共同形成 -CH2-CH2-，X1，连接在芳香环的2或3位，代表键，此时X2代表氢、卤素、烷基、烷氧基、羟基、硝基、氰基或可选择地取代的氨基，或X1 和 X2，与它们连接在芳香环的2、3或4位的两个相邻碳原子一起，形成一个(C4-C7)环烷基团，其中环烷基环的一个或两个-CH2-可选择地被氧或NH取代，X3 代表氢、卤素、烷基、烷氧基、羟基、硝基、氰基或可选择地取代的氨基，G 代表从中选择的一个基团：其中：虚线表示双键的可选存在，Alk 代表直链或支链(C1-C6)烷基，n 为0或1，T3 代表烷基、可选择地取代的芳基、可选择地取代的芳基烷基、可选择地取代的杂环芳基或可选择地取代的杂环芳基烷基，T4 代表烷基、可选择地取代的芳基、可选择地取代的芳基烷基、可选择地取代的杂环芳基或可选择地取代的杂环芳基烷基，以及含有这些化合物的药物制品作为双α2/5-HT2C拮抗受体是有用的。
• Anti-hypertensive benzodioxan derivatives
  申请人：Bouchara; Emile

  公开号：US04432984A1

  公开（公告）日：1984-02-21

  This invention relates to benzodioxanylalkylpiperidines, to processes for producing them and to the pharmaceutical compositions containing such compounds as active ingredient. This invention also relates to a method for treating hypertension in hypertensive mammals.

  本发明涉及苯二氧杂基烷基哌啶类化合物，涉及生产这些化合物的方法以及含有这些化合物作为活性成分的药物组合物。本发明还涉及一种治疗高血压的方法，适用于高血压哺乳动物。
• 1,4-Benzodioxins—I
  作者：A.R. Katrizky、M.J. Sewell、R.D. Topsom、A.M. Monro、G.W.H. Potter

  DOI：10.1016/0040-4020(66)80067-4

  日期：1966.1

  1,4-Benzodioxin and its 2-phenyl derivative can be prepared by the dehyration of their respective 2-hydroxy compounds under suitable conditions. 2-Methyl-1,4-benzodioxin can be similarly prepared but is more readily obtained by the isomerization of 2-methylene-1,4-benzodioxan. The structures of these compounds have been authenticated by analysis, UV, PMR and IR spectroscopy and by hydrogenation experiments

  1，4-苯并二恶英及其2-苯基衍生物可通过在适当条件下将其各自的2-羟基化合物脱水而制得。可以类似地制备2-甲基-1，4-苯并二恶英，但是更容易通过2-亚甲基-1，4-苯并二恶烷的异构化获得。这些化合物的结构已通过分析，UV，PMR和IR光谱以及氢化实验进行了鉴定。显示2-羟基-1,4-苯并二恶烷原样存在，而不是它们的开链羰基互变异构体。讨论了上述化合物的制备和结构的先前描述。